Oh, The Places Dermatology Will Go in 2024!
The Dermatology Digest
FEBRUARY 8, 2024
Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., New systemic agents and even new concepts in the prevention of atopic dermatitis and the microbiome seem just around the corner too, Dr. Lio says. “We Food and Drug Administration (FDA) recently OKed a label update for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc.,
Let's personalize your content